Clinical Trial Details
| Trial ID: | L3125 |
| Source ID: | NCT02606357 |
| Associated Drug: | Insulin Glargine |
| Title: | Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan |
| Acronym: | NEWLAN |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: INSULIN GLARGINE |
| Outcome Measures: | Primary: Change from baseline in HbA1c, Baseline, 6 months | Secondary: - Percentage of patients achieving target of HbA1c <7%, 6 months|- Change from baseline in fasting plasma glucose values, Baseline, 3 months, and 6 months|- Percentage of patients with hypoglycemic events, Baseline, 6 months|- Change from baseline in body weight, Baseline, 3 months and 6 months|- Number of patients with adverse events, Baseline, 6 months|- Change in dose of insulin glargine, 3 months and 6 months|- Change in the titration doses used (if any), 6 months|- Time to reach control, 6 months |
| Sponsor/Collaborators: | Sponsor: Sanofi |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 242 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2015-11-22 |
| Completion Date: | 2017-11-27 |
| Results First Posted: | |
| Last Update Posted: | 2018-10-12 |
| Locations: | JORDAN, Jordan, Jordan |
| URL: | https://clinicaltrials.gov/show/NCT02606357 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|